Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - upadacitinibum - retardtablette - upadacitinibum 15 mg per upadacitinibum hemihydricum, cellulosum microcristallinum, hypromellosum, mannitolum, acido tartaricum, silice colloidalis anhydrica, magnesio stearas, poli(alcole vinylicus), macrogolum 3350, talco, e 171, e 172, per compresso haze. - selettiva immunosoppressore - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artrite, reumatoide - immunosoppressori - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Unione Europea - italiano - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatite, atopica - altri preparati dermatologici - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - abrocitinibum - compresse rivestite con film - abrocitinibum 50 mg, cellulosum microcristallinum, calcii hydrogenophosphas, carboxymethylamylum natricum a corresp. natrium 0.814 mg, magnesii stearas, Überzug: hypromellosum, e 171, lactosum monohydricum 1.365 mg, macrogolum 3350, triacetinum, e 172 (rubrum), pro compresso obducto. - atopische dermatitis - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - abrocitinibum - compresse rivestite con film - abrocitinibum 100 mg, cellulosum microcristallinum, calcii hydrogenophosphas, carboxymethylamylum natricum a corresp. natrium 1.629 mg, magnesii stearas, Überzug: hypromellosum, e 171, lactosum monohydricum 2.73 mg, macrogolum 3350, triacetinum, e 172 (rubrum), pro compresso obducto. - atopische dermatitis - synthetika